Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Scancell
Acquired Company
Neuphoria Therapeutics
OxfordBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareTherapeuticsPharmaceuticalDescription
Scancell Holdings is planning an all-share merger with Neuphoria Therapeutics, which will result in Neuphoria becoming a wholly owned subsidiary. The merger aims to facilitate a Nasdaq listing and secure new funding for Scancell. Shareholder approval is pending, with completion contingent on various regulatory processes. A late-stage melanoma trial is expected to commence before the year's end.
Fundz sees it the moment Scancell makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Neuphoria Therapeutics?
Neuphoria Therapeutics was acquired by Scancell, based in Oxford. The deal was reported on October 12, 2026. The company’s innovative products target post-translational modifications of proteins and lipids. Scancell is privately held and operates in Biotechnology.
When did Scancell acquire Neuphoria Therapeutics?
Scancell's acquisition of Neuphoria Therapeutics was reported on October 12, 2026. Scancell Holdings is planning an all-share merger with Neuphoria Therapeutics, which will result in Neuphoria becoming a wholly owned subsidiary. The merger aims to facilitate a Nasdaq listing and secure new funding for Scancell. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Neuphoria Therapeutics do?
Neuphoria Therapeutics Inc. is a Delaware corporation focused on innovative therapeutics. The company is dedicated to advancing treatments in the healthcare sector. It operates primarily through the development of specialized pharmaceutical products. It is publicly traded (NEUP), operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.